Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Summary

The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify local therapy and improve outcomes.

Timeline

Start

2019-07-01

Primary completion

2022-01-01

Completion

2023-01-01

Outcome

Outcome not reported

Stopped: “Study is being abandoned.”

Drugs

Indications